Русский
A patient with systemic lupus erythematosus and lupus nephritis: the potentials for biological therapy
DOI: https://dx.doi.org/10.18565/nephrology.2021.3.44-48
N. Damyanov, I.B. Vinogradova, A.V. Bezgin, L.A. Knyazeva
1) University of Belgrade, Faculty of Medicine, Department of Rheumatology, Belgrade, Serbia; 2) Ulyanovsk Regional Clinical Hospital, Department of Rheumatology, Ulyanovsk, Russia; 3) Kursk Regional Clinical Hospital, Department of Nephrology, Kursk, Russia; 4) OOO Medical Center № 1, Department of Rheumatology, Kursk, Russia
Material and methods. The study included 18 patients with SLE and lupus kidney disease who received belimumab in addition to standard therapy. Evaluation of immunological parameters (anti-native double-stranded DNA antibody titers, C3, C4 complement component levels), biochemical parameters (cholesterol, creatinine, total blood protein levels), changes in clinical urinalysis (proteinuria, cylindruria, leukocyturia, erythrocyturia) was performed; dynamics of glomerular filtration rate (GFR), daily proteinuria and the SELENA-SLEDAI index, obtained in different periods from the start of treatment with belimumab (0, 2, 6 and 12 months) were analyzed.
Results. The positive dynamics of clinical and laboratory symptoms (a decrease in the main disease symptoms, a positive dynamics of laboratory parameters and an improvement in the general condition) of patients were revealed.
Conclusion. The use of belimumab at a dose of 10 mg/kg in addition to standard therapy for patients with SLE and LN reduces the clinical and immunological activity of SLE, decreases the level of daily proteinuria, decreases the creatinine level, and allows deescalating the dose of glucocorticosteroids taken.
About the Autors
Nemanja Damyanov – Dr.Sci. (Med.), Professor, Head of the Department of Rheumatology, Faculty of Medicine, University of Belgrade, Serbia, Chairman of the EULAR Committee on Continuous Medical Education; e-mail: nemanjadamjanov@yahoo.com.
Irina B. Vinogradova – Cand. Sci. (Med.), Head of the Department of Rheumatology, Ulyanovsk Regional Clinical Hospital, Chief External Expert in Rheumatology
of the Ulyanovsk Region, Chief Rheumatologist of the Volga Federal District, Ulyanovsk, Russia; e-mail: kazvin@yandex.ru.
Artem V. Bezgin – Dr. Sci. (Med.), Nephrologist, Department of Nephrology, Kursk Regional Clinical Hospital, Kursk, Russia; e-mail: bezgin_artem@inbox.ru.
Larisa A. Knyazeva – Dr. Sci. (Med.), Professor, Head of the Department of Rheumatology, OOO "Medical Center № 1", Scientific Expert at GSK "Rheumatology", Kursk, Russia; e-mail: larisa.x.kniazeva@gsk.com.
Similar Articles
